

Supplementary Table 1. Clinical and genetic data of probands with novel variants in potential diabetes genes.

Patient ID	Clinical data							Autoimmune markers (+/-)		Treatment			Genetic data		
	Age group at diabetes Dx	BG at Dx, mmol/L	Ketosis at Dx, Y/N	Diabetes in Family Hx, Y/N	Age group at analysis	HbA1c at analysis, % (mmol/mol)	BMI Z-score	IAA	ZnT8A	Insulin, Y/N	Dose of insulin, U/kg/d	Other	Gene	DNA change	Protein effect
1	IV	6.2	Y	N	IV	11.5 (102)	-1.1	+	+	Y	0.9	-	<i>RFX2</i>	c.1894G>A	p.Ala632Thr
2	IV	15.8	Y	N	IV	8.1 (65)	-1.1	+	-	Y	0.6	-	<i>RREB1</i>	c.3218C>T	p.Ser1073Leu
3	II	26	Y	N	III	7 (53)	-0.86	+	-	Y	0.5	-	<i>SLC5A1</i>	c.932A>T	p.Lys311Met
4	III	NA	N	N	III	7.2 (55)	-1.57	+	-	Y	0.6	-	<i>GCKR</i>	c.1484T>G	p.Val495Gly
5	III	29	Y	N	III	5.8 (40)	1.53	-	-	Y	0.2	-	<i>MC4R</i>	c.230C>T	p.Ser77Leu
6	III	8	N	Y	III	NA	0.34	-	-	N	-	none	<i>CASP10</i>	c.104del	p.Asp35Valfs*10
7	V	10.9	N	Y	VI	11 (97)	1.05	-	-	Y	0.8	-	<i>TMPRSS6</i>	p.Lys755Glu	0.998
8	V	32	N	N	V	6.7 (50)	-1.67	-	-	Y	0.3	-	<i>HGFAC</i>	c.711C>G	p.Cys237Trp
9	III	NA	N	Y	VI	11.6 (103)	0.79	-	-	Y	1.0	-	<i>DACHI</i>	c.454_456dup	p.Ser152dup
10	V	14	Y	Y	VI	8.9 (74)	-1.29	+	-	Y	0.4	-	<i>SLC5A1</i>	c.1415T>C	p.Leu472Pro
11	II	18	N	N	VI	7.4 (57)	2.41	+	-	Y	1.0	-	<i>ZBED3</i>	c.211C>G	p.Leu71Val
12	V	NA	N	Y	VI	8.5 (69)	-1.14	+	-	Y	1.1	-	<i>SLC5A1</i>	c.1415T>C	p.Leu472Pro

Dx, diagnosis; BG, blood glucose; Y, yes; N, no; Hx, history; HbA1c, glycosylated haemoglobin; BMI, body mass index; IAA, insulin autoantibodies; ZnT8A, zinc transporter 8 autoantibodies.

Age groups: I – under 0.5 years; II – 0.5 – 4 years; III – 5 – 9 years; IV – 10 – 14 years; V – 15 – 19 years; VI – ≥ 20 years.